QR-Code

CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis

Abstract Background CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, has demonstrated significantly improved overall survival in acute myeloid leukemia (AML) compared with 7 + 3, but its impact on cardiac function remains unclear. In a pos...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Joshua D. Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Shunsuke Eguchi, Yoshiyuki Orihara, Nalina Dronamraju, Sonja Dhani, Stefan Faderl, Tara L. Lin, Geoffrey L. Uy, Jeffrey E. Lancet, Jorge E. Cortes
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2025-11-01
Schriftenreihe:Cardio-Oncology
Schlagworte:
Cardiotoxicity
CPX-351
7 + 3
Acute myeloid leukemia
Ejection fraction
Anthracyclines
Online-Zugang:https://doi.org/10.1186/s40959-025-00421-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge